Evidence map›Paper›PMID 24710920›Full record

Trial reportHIV clinical trials

Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening.

Estelle Piwowar-Manning, Jessica M Fogel, Oliver Laeyendecker, Shauna Wolf, Vanessa Cummings, Mark A Marzinke, William Clarke, Autumn Breaud, Sarah Wendel, Lei Wang and 10 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in HIV clinical trials. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Update on HIV prevention and management in pregnancy Number 10 - 2025.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2025
    Article
  6. Article
  7. Article
  8. Rapid Serological Tests Ineffectively Screen for HIV Exposure in HIV-Positive Infants.Journal of acquired immune deficiency syndromes (1999) · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Determination of HIV Status in African Adults With Discordant HIV Rapid Tests.Journal of acquired immune deficiency syndromes (1999) · 2015
    Article
  13. Performance of the fourth-generation Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay for diagnosis of HIV infection in Southern Africa.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2015
    Article
  14. Low-level Viremia early in HIV infection.Journal of acquired immune deficiency syndromes (1999) · 2014
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 11 institutions in 1 country.

Estelle Piwowar-ManningDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jessica M FogelDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Oliver LaeyendeckerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Shauna WolfDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Vanessa CummingsDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Mark A MarzinkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
William ClarkeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Autumn BreaudDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sarah WendelLaboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Lei WangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Priscilla SwansonInfectious Disease Research, Abbott Diagnostics, Abbott Park, Illinois.
John HackettInfectious Disease Research, Abbott Diagnostics, Abbott Park, Illinois.
Sharon MannheimerDepartment of Medicine, Harlem Hospital, Columbia University, Mailman School of Public Health, New York, New York.
Carlos Del RioDepartment of Global Health, Emory University Rollins School of Public Health, Atlanta, Georgia.
Irene KuoDepartment of Epidemiology and Biostatistics, The George Washington University, Washington, DC.
Nina T HarawaDepartment of Research, Charles R. Drew University of Medicine and Science, Los Angeles, California.
Beryl A KoblinLaboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York.
Richard MooreDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Joel N BlanksonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Susan H EshlemanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins Medicine · USJohns Hopkins University · USAbbott (United States) · USCharles R. Drew University of Medicine and Science · USColumbia University · USEmory University · USFred Hutch Cancer Center · USGeorge Washington University · USNational Institutes of Health · USNew York Blood Center · USUniversity of Baltimore · US

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
Emory HIV/AIDS Clinical Trials UnitUM1AI069418 · NIAID · EMORY UNIVERSITY · PI Colleen F Kelley · 2012 to 2026
$46.0M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Emory HIV/AIDS Clinical Trials UnitU01AI069418 · NIAID · EMORY UNIVERSITY · PI LENNOX, JEFFREY · 2007 to 2011
$13.9M
HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICER01DA011602 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 1998 to 2013
$10.8M
CD8+ T cell mediated inhibition of HIV-1 replication in Elite SuppressorsR01AI080328 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BLANKSON, JOEL N · 2009 to 2012
$1.3M
Intramural NIH HHS ZIA AI000361NCATS NIH HHS UL1 TR001079NIAID NIH HHS P30 AI094189NIAID NIH HHS P30-AI094189NIAID NIH HHS R01 AI080328NIAID NIH HHS R01-AI080328NIAID NIH HHS U01 AI069418NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI069418NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069470NIDA NIH HHS R01 DA011602NIDA NIH HHS R01-DA011602NIDA NIH HHS U01 DA036935
6 · The paper itself

Abstract

backgroundIn the HIV Prevention Trials Network (HPTN) 061 study, 8 (2.3%) of 348 HIV-infected participants identified as HIV uninfected at study enrollment using a single HIV rapid test for screening were found to be HIV infected after additional testing.

objectivesTo evaluate the performance of different HIV assays for detection of HIV infection in HPTN 061 participants with missed infection and individuals with viral suppression.

methodsPlasma samples from 8 HPTN 061 participants, 17 elite controllers, and 101 individuals on antiretroviral treatment (ART) were tested for HIV with 3 rapid tests, 2 laboratory-based immunoassays, and a Western blot assay. The HPTN 061 samples were also tested with 2 HIV RNA assays and an antiretroviral drug assay.

resultsOf the 8 HPTN 061 participants with missed infection, 1 was an elite controller, 1 was taking ART, 2 were missed because of testing or clerical errors, 1 had recent HIV infection (identified using a multi-assay algorithm), and 3 had acute HIV infection. Two (1.7%) of 118 individuals with viral suppression (both taking ART) had at least 1 false-negative test.

conclusionsIn clinical trials, HIV infections can be missed for a variety of reasons. Using more than one assay to screen for HIV infection may reduce the number of missed infections.

Indexed as

AdultAntibodies, ViralAnti-HIV AgentsBlotting, WesternCohort StudiesFalse Negative ReactionsFemaleHIV-1HIV InfectionsHumansImmunoassayMaleMass ScreeningMiddle AgedRNA, ViralSensitivity and SpecificityAntibodies, ViralAnti-HIV AgentsRNA, Viralantiretroviral therapyelite controllerHIVrapid testviral suppression

Identifiers

PMID24710920
PMCPMC4167641
OpenAlexW2090841959

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.